BR112022020644A2 - Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial - Google Patents

Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial

Info

Publication number
BR112022020644A2
BR112022020644A2 BR112022020644A BR112022020644A BR112022020644A2 BR 112022020644 A2 BR112022020644 A2 BR 112022020644A2 BR 112022020644 A BR112022020644 A BR 112022020644A BR 112022020644 A BR112022020644 A BR 112022020644A BR 112022020644 A2 BR112022020644 A2 BR 112022020644A2
Authority
BR
Brazil
Prior art keywords
derivatives
mitochondrial dysfunction
pyrrolidin
oxazole
trifluoromethyl
Prior art date
Application number
BR112022020644A
Other languages
English (en)
Inventor
Andrew Luckhurst Christopher
Ian Kemp Mark
William Thompson Paul
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008051.1A external-priority patent/GB202008051D0/en
Priority claimed from GBGB2016709.4A external-priority patent/GB202016709D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of BR112022020644A2 publication Critical patent/BR112022020644A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE N-(1-CIANO-PIRROLIDIN-3-IL)-5-(3-(TRIFLUOROMETIL)FENIL) OXAZOL-2-CARBOXAMIDA E OS CORRESPONDENTES DERIVADOS DE OXADIAZOL COMO INIBIDORES DE USP30 PARA O TRATAMENTO DE DISFUNÇÃO MITOCONDRIAL. A presente invenção refere-se a uma classe de N-cianopirrolidinas com atividade como inibidores da enzima deubiquitilante USP30, tendo utilidade em diversas áreas terapêuticas, incluindo condições envolvendo disfunção mitocondrial, câncer e fibrose: .
BR112022020644A 2020-05-28 2021-05-27 Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial BR112022020644A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2008051.1A GB202008051D0 (en) 2020-05-28 2020-05-28 Novel compounds
GBGB2016709.4A GB202016709D0 (en) 2020-10-21 2020-10-21 Novel compounds
PCT/EP2021/064166 WO2021239863A1 (en) 2020-05-28 2021-05-27 N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction

Publications (1)

Publication Number Publication Date
BR112022020644A2 true BR112022020644A2 (pt) 2022-12-06

Family

ID=76444366

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020644A BR112022020644A2 (pt) 2020-05-28 2021-05-27 Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial

Country Status (12)

Country Link
US (1) US20230219939A1 (pt)
EP (1) EP4157834A1 (pt)
JP (1) JP2023527025A (pt)
KR (1) KR20230016674A (pt)
CN (1) CN115667252A (pt)
AU (1) AU2021279199A1 (pt)
BR (1) BR112022020644A2 (pt)
CA (1) CA3185027A1 (pt)
CO (1) CO2022014135A2 (pt)
IL (1) IL298526A (pt)
MX (1) MX2022014429A (pt)
WO (1) WO2021239863A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015003081A (es) * 2012-09-17 2015-07-14 Hoffmann La Roche Inhibidores de usp30 y metodos de uso.
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US6835727B2 (en) 2000-04-06 2004-12-28 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
BRPI0709950A2 (pt) 2006-04-13 2011-08-02 Actelion Pharmaceuticals Ltd uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
UY31299A1 (es) 2007-08-20 2009-03-31 Nuevos inhibidores de catepsina y su uso
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
TW201002318A (en) 2008-04-18 2010-01-16 Glaxo Group Ltd Cathepsin C inhibitors
WO2009129371A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
KR20160036053A (ko) 2013-07-31 2016-04-01 메르크 파텐트 게엠베하 Btk 저해제로서 피리딘, 피리미딘, 및 피라진, 및 이들의 용도
EP3145505A4 (en) 2014-05-19 2018-02-28 Northeastern University N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
EP3148572A4 (en) 2014-05-27 2017-12-27 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
NZ736450A (en) 2015-03-30 2022-04-29 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
US10669234B2 (en) 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
US11352339B2 (en) 2016-03-24 2022-06-07 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as DUB inhibitors
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
EA202090871A1 (ru) 2017-10-06 2020-07-03 Форма Терапьютикс, Инк. Ингибирование убиквитин-специфической пептидазы 30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
MX2020012180A (es) 2018-05-17 2021-01-29 Forma Therapeutics Inc Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina.
US11572374B2 (en) 2018-08-14 2023-02-07 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
EP4218934A1 (en) 2018-10-05 2023-08-02 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
CN115667252A (zh) 2023-01-31
MX2022014429A (es) 2022-12-07
WO2021239863A1 (en) 2021-12-02
JP2023527025A (ja) 2023-06-26
KR20230016674A (ko) 2023-02-02
EP4157834A1 (en) 2023-04-05
CO2022014135A2 (es) 2022-10-31
AU2021279199A1 (en) 2023-01-19
IL298526A (en) 2023-01-01
US20230219939A1 (en) 2023-07-13
CA3185027A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
BR112022020644A2 (pt) Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial
CY1124078T1 (el) Συνθεσεις που περιλαμβανουν αναστολεα λυσινης ειδικης απομεθυλασης-1 που εχει δακτυλιο πυριμιδινης και χρηση αυτων στη θεραπεια καρκινου
SA519402076B1 (ar) مشتقات فينيل جديدة
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
CY1119170T1 (el) Ενωση γουανιδινης
BR112021020682A2 (pt) Derivados de 1,3,4-oxadiazol como inibidores de histona deacetilase
ECSP12012056A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
PA8620901A1 (es) Derivados de prostaglandinas
WO2014141110A3 (en) Aminonitriles as kynurenine pathway inhibitors
BR112022003527A2 (pt) Cianopirrolidinas substituídas com atividade como inibidores de usp30
CO6351714A2 (es) Tratamiento para diabetes en pacientes inapropiados para terapia con metformina
DE602007008237D1 (de) Benzamidderivate und assoziierte verwendungen
EA202090977A1 (ru) Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild)
CL2012000326A1 (es) Compuestos derivados de heterociclos que presentan n como heteroátomo, n-[2-hidroxi-2-fenil-(4-oxadiazol o 4-tiadiazol)]etil sustituidos, agonistas del receptor de esfingosina-1-fosfato; composición farmacéutica; y su uso para tratar una enfermedad autoinmunitaria o inflamatoria crónica.
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112012004851B8 (pt) uso de um derivado de tiazol
CY1120003T1 (el) Αντιμικροβιακη πρωτεϊνη
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
PE20211818A1 (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal
BR112022008938A2 (pt) Derivados de 1-aminossulfonil-2-carboxipirrol como inibidores de metalo-beta-lactamase
CO2021004004A2 (es) Composición tópica inyectable
CO2022017233A2 (es) 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis
BR112022020058A2 (pt) N-cianopirrolidinas com atividade como inibidores de usp30
BR112013008355A2 (pt) formas cristalinas do sal de sódio de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético
CO2022011388A2 (es) Inhibidores heterocíclicos de pad4